Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.71 |
| ▸ | LMNA | P02545 | 3/20 | 0.71 |
| ▸ | TSHR | P16473 | 2/20 | 0.71 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.63 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | CES2 | O00748 | 1/20 | 0.61 |
| ▸ | CES1 | P23141 | 1/20 | 0.61 |
| ▸ | PARP1 | P09874 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.56 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1987981 | 0.90 | HPGD (0.65) | HPGDLMNATSHROPRM1OPRD1 | |
| SCHEMBL21556183 | 0.87 | HSD17B10 (0.58) | HPGDLMNATSHROPRM1OPRD1 | |
| SCHEMBL10013749 | 0.87 | HPGD (0.59) | HPGDLMNATSHROPRM1OPRD1 | |
| SCHEMBL9416561 | 0.87 | TSHR (0.64) | HPGDLMNATSHROPRM1OPRD1 | |
| SCHEMBL7531598 | 0.87 | HPGD (0.60) | HPGDLMNATSHROPRM1OPRD1 | |
| SCHEMBL15563100 | 0.84 | HPGD (0.57) | HPGDLMNATSHROPRM1OPRD1 | |
| SCHEMBL5095020 | 0.84 | HPGD (0.59) | HPGDLMNATSHROPRM1OPRD1 | |
| SCHEMBL7406512 | 0.84 | HPGD (0.79) | HPGDLMNATSHROPRM1OPRD1 | |
| SCHEMBL7269968 | 0.83 | OPRD1 (0.56) | HPGDLMNATSHROPRM1OPRD1 | |
| SCHEMBL7269978 | 0.83 | OPRD1 (0.56) | HPGDLMNATSHROPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115413278-A | Novel pyrimidine derivative and composition for preventing or treating neurodegenerative disease and cancer comprising same | 丸仁制药株式会社 | 2022-11-29 | — | — | CN | claimed |
| CN-104860891-A | Arylaminopyrimidine compound and use thereof and pharmaceutical composition and medicinal composition prepared from arylaminopyrimidine compound | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO LTD | 2015-08-26 | — | — | CN | claimed |
| CN-102753547-B | Triazolopyridine derivatives | BAYER IP GMBH | 2015-06-03 | — | — | CN | claimed |
| CN-102753547-A | Triazolopyridine derivatives | BAYER SCHERING PHARMA AG | 2012-10-24 | — | — | CN | claimed |
| CN-115697969-A | 7-or 8-hydroxy-isoquinoline and 7-or 8-hydroxy-quinoline derivatives as alpha-1 antitrypsin modulators for the treatment of alpha-1 antitrypsin deficiency (AATD) | 弗特克斯药品有限公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-115413278-A | Novel pyrimidine derivative and composition for preventing or treating neurodegenerative disease and cancer comprising same | 丸仁制药株式会社 | 2022-11-29 | — | — | CN | disclosed |
| CN-105408332-A | Substituted triazolopyridines | Bayer Pharma AG | 2016-03-16 | — | — | CN | disclosed |
| CN-103608350-B | Triazolopyridine compounds | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-25 | — | — | CN | disclosed |
| CN-104860891-A | Arylaminopyrimidine compound and use thereof and pharmaceutical composition and medicinal composition prepared from arylaminopyrimidine compound | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO LTD | 2015-08-26 | — | — | CN | disclosed |
| US-20150166500-A1 | Compounds and Methods for Catalytic Directed ortho Substitution of Aromatic Amides and Esters | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2015-06-18 | — | — | US | disclosed |
| EP-2493877-B1 | PYRIMIDINE COMPOUNDS AS DELTA OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-17 | — | — | EP | disclosed |
| EP-2493877-B1 | PYRIMIDINE COMPOUNDS AS DELTA OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-17 | — | — | EP | disclosed |
| CN-1147298-C | Prevention and curing agent for c attenuation living vaccine | 卫材株式会社 | 2004-04-28 | — | — | CN | disclosed |
| WO-1998039337-A1 | PROCESS FOR SYNTHESISING PURE ENANTIOMER ANTHRACYCLINE | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-09-11 | — | — | WO | disclosed |
| US-5760054-A | BENIGN PROSTATIC HYPERTROPHY | MERCK & CO., INC. (US) | 1998-06-02 | — | — | US | disclosed |
| EP-0755392-A4 | ALPHA1C ADRENERGIC RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 1997-05-02 | — | — | EP | disclosed |
| EP-0755392-A1 | ALPHA1C ADRENERGIC RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 1997-01-29 | — | — | EP | disclosed |
| CN-1137895-A | Prevention and curing agent for c attenuation living vaccine | EISAI CO LTD (JP) | 1996-12-18 | — | — | CN | disclosed |
| WO-1995028397-A1 | ALPHA1C ADRENERGIC RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1995-10-26 | — | — | WO | disclosed |
| EP-0355750-A1 | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process | WARNER-LAMBERT COMPANY (US) | 1990-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166500-A1 | Compounds and Methods for Catalytic Directed ortho Substitution of Aromatic Amides and Esters | DDC, AOC2, AOC3 | HPGD 2168/4885LMNA 2879/4885TSHR 2895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.